We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
American Vanguard (AVD) Q2 Earnings and Sales Miss Estimates
Read MoreHide Full Article
American Vanguard Corporation (AVD - Free Report) logged a loss of 42 cents per share in the second quarter of 2024 compared with a loss of 4 cents a year ago.
Barring one-time items, adjusted loss came in at 9 cents per share for the quarter. It was wider than the Zacks Consensus Estimate of a loss of a penny per share.
Revenues were $128.2 million for the reported quarter, down around 3% year over year. It missed the Zacks Consensus Estimate of $134.2 million. The top line was impacted by unfavorable market conditions in the reported quarter. AVD, however, registered double-digit sales increases in its domestic non-crop business and Green Solutions products, aided by strong demand in Central America.
American Vanguard Corporation Price, Consensus and EPS Surprise
Revenues from American Vanguard’s U.S. crop business in the reported quarter went down roughly 7% year over year to around $52.3 million. Within the U.S. Crop business, AVD recorded higher sales in the granular insecticide category, partly offset by lower sales of Aztec and soil fumigants.
Sales from the U.S. non-crop business rose around 13% year over year to around $19 million. Higher biologicals and pest strip sales were partly offset by lower Dibrom mosquito adulticide sales.
Revenues from international businesses were down around 5% year over year to around $56.9 million. Sales were impacted by lower herbicides sales.
Financials
American Vanguard ended the quarter with cash and cash equivalents of roughly $17.9 million, up around 31% sequentially. Long-term debt was around $211.3 million, up around 13% sequentially.
Outlook
AVD lowered its full-year 2024 guidance for adjusted EBITDA to $40-$50 million from its previous estimate of $60-$70 million. It now sees net sales for the year to be down 2%-to-flat compared with its earlier estimate of sales growth of 6-9%. The revised guidance is based on the current state of the market and the company’s projected demand, which it expects to be stable.
Price Performance
American Vanguard’s shares have lost 62.8% in a year against a 13.9% decline of the industry.
Quaker Chemical Corporation (KWR - Free Report) logged adjusted earnings for the second quarter of $2.13 per share, missing the Zacks Consensus Estimate of $2.21. KWR expects to deliver earnings growth in 2024, notwithstanding the challenging end-market environment, which it expects to continue through the end of the year.
Ingevity Corporation (NGVT - Free Report) reported adjusted earnings of $1.01 per share for the second quarter, down from $1.41 a year ago. The figure missed the Zacks Consensus Estimate of $1.05.
NGVT revised its sales guidance for 2024 to $1.4-$1.5 billion and adjusted EBITDA outlook to $350-$360 million.
Element Solutions Inc’s (ESI - Free Report) adjusted earnings came in at 36 cents per share for the second quarter. The figure beat the Zacks Consensus Estimate of 35 cents.
Element Solutions now expects adjusted EBITDA in the range of $530-$545 million for 2024. ESI anticipates generating a free cash flow in the range of $280-$300 million for 2024.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
American Vanguard (AVD) Q2 Earnings and Sales Miss Estimates
American Vanguard Corporation (AVD - Free Report) logged a loss of 42 cents per share in the second quarter of 2024 compared with a loss of 4 cents a year ago.
Barring one-time items, adjusted loss came in at 9 cents per share for the quarter. It was wider than the Zacks Consensus Estimate of a loss of a penny per share.
Revenues were $128.2 million for the reported quarter, down around 3% year over year. It missed the Zacks Consensus Estimate of $134.2 million. The top line was impacted by unfavorable market conditions in the reported quarter. AVD, however, registered double-digit sales increases in its domestic non-crop business and Green Solutions products, aided by strong demand in Central America.
American Vanguard Corporation Price, Consensus and EPS Surprise
American Vanguard Corporation price-consensus-eps-surprise-chart | American Vanguard Corporation Quote
Sales by Regions
Revenues from American Vanguard’s U.S. crop business in the reported quarter went down roughly 7% year over year to around $52.3 million. Within the U.S. Crop business, AVD recorded higher sales in the granular insecticide category, partly offset by lower sales of Aztec and soil fumigants.
Sales from the U.S. non-crop business rose around 13% year over year to around $19 million. Higher biologicals and pest strip sales were partly offset by lower Dibrom mosquito adulticide sales.
Revenues from international businesses were down around 5% year over year to around $56.9 million. Sales were impacted by lower herbicides sales.
Financials
American Vanguard ended the quarter with cash and cash equivalents of roughly $17.9 million, up around 31% sequentially. Long-term debt was around $211.3 million, up around 13% sequentially.
Outlook
AVD lowered its full-year 2024 guidance for adjusted EBITDA to $40-$50 million from its previous estimate of $60-$70 million. It now sees net sales for the year to be down 2%-to-flat compared with its earlier estimate of sales growth of 6-9%. The revised guidance is based on the current state of the market and the company’s projected demand, which it expects to be stable.
Price Performance
American Vanguard’s shares have lost 62.8% in a year against a 13.9% decline of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Other Chemicals Releases
AVD currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quaker Chemical Corporation (KWR - Free Report) logged adjusted earnings for the second quarter of $2.13 per share, missing the Zacks Consensus Estimate of $2.21. KWR expects to deliver earnings growth in 2024, notwithstanding the challenging end-market environment, which it expects to continue through the end of the year.
Ingevity Corporation (NGVT - Free Report) reported adjusted earnings of $1.01 per share for the second quarter, down from $1.41 a year ago. The figure missed the Zacks Consensus Estimate of $1.05.
NGVT revised its sales guidance for 2024 to $1.4-$1.5 billion and adjusted EBITDA outlook to $350-$360 million.
Element Solutions Inc’s (ESI - Free Report) adjusted earnings came in at 36 cents per share for the second quarter. The figure beat the Zacks Consensus Estimate of 35 cents.
Element Solutions now expects adjusted EBITDA in the range of $530-$545 million for 2024. ESI anticipates generating a free cash flow in the range of $280-$300 million for 2024.